MIGS Case Studies with Dr. Ristvedt and Dr. O’Dell -

Name: MIGS Case Studies with Dr. Ristvedt and Dr. O’Dell
Uploaded: 2021-03-01T05:00:00+00:00
Duration: 30 min 48 s
Description: In this episode, faculty review mild, moderate and severe cases of glaucoma in phakic patients.Supported by an unrestricted educational grant from Sight Sc

Media formats available:

Details

Presenters

Download PDF

Overview
In this episode, faculty review mild, moderate and severe cases of glaucoma in phakic patients.
Supported by an unrestricted educational grant from Sight Sciences.
Learning Objectives
Compare and contrast standalone and cataract MIGS (minimally invasive glaucoma surgery) patients: Patient demographics, surgical procedure, and patient follow-up parameters Understand the MIGS patient journey: How to identify ideal MIGS patients, educate and set expectations, and manage these patients postop
Accreditation
There is no credit associated with this course.
Faculty and Disclosures
Deborah Ristvedt, DO
Ophthalmologist Surgeon
Vance Thompson Vision
Bozeman, MT

Leslie O’Dell, OD, FAAO
Clinical Director
Medical Optometry America
York, PA

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Deborah Ristvedt, DO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Glaukos, and Sight Sciences. Grant/Research Support: Allergan. Speaker’s Bureau: Alcon, and Glaukos.
Leslie O’Dell, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie, Allergan, Bausch + Lomb, Dompe, Eyevance, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, Oyster Point, Pharma, Sun Pharmaceutical Industries, Sight Sciences, and Tarsus. Speaker's Bureau: Allergan, Johnson & Johnson Vision, and Sight Sciences.
Deborah Ristvedt, DO Vance Thompson Vision Alexandria, MN Leslie O'Dell, OD Clinical Director of Medical Optometry America York, PAD DISCLOSURE POLICY It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity. The following faculty/staff members have the following financial relationships with commercial interests:Leslie O’Dell, OD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie and Sight Sciences. Deborah Ristvedt, OD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Glaukos, and Sight Sciences. Grant/Research Support: Allergan. Speaker’s Bureau: Alcon, and Glaukos. The Evolve Medical Education or The Fundingsland Group staff and planners have no financial relationships with commercial interests.
Disclaimer
OFF-LABEL STATEMENT This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. DISCLAIMER The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group or Sight Sciences.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 03/01/2021
Expiration Date: 12/30/2022

Deborah Ristvedt, DO

Guest

Leslie O’Dell, OD, FAAO

Guest

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Catching Demodex in the Act
Catching Demodex in the Act
MinuteCE®
Catching Demodex in the Act
Douglas K. Devries, OD; Cecelia Koetting, OD, FAAO
1.00 program credit
- Douglas K. Devries, OD
- Cecelia Koetting, OD, FAAO
1.00 program credit
At the Intersection of DB, DED, MGD, and Other Forms of Blepharitis
At the Intersection of DB, DED, MGD, and Other Forms of Blepharitis
MinuteCE®
At the Intersection of DB, DED, MGD, and Other Forms of Blepharitis
Douglas K. Devries, OD; Cecelia Koetting, OD, FAAO
1.00 program credit
- Douglas K. Devries, OD
- Cecelia Koetting, OD, FAAO
1.00 program credit
The Neverending Journey: A 66-Year-Old Patient Who Has Undergone Several Rounds of Tea Tree Oil–Based Treatment
The Neverending Journey: A 66-Year-Old Patient Who Has Undergone Several Rounds of Tea Tree Oil–Based Treatment
MinuteCE®
The Neverending Journey: A 66-Year-Old Patient Who Has Undergone Several Rounds of Tea Tree Oil–Based Treatment
Douglas K. Devries, OD; Cecelia Koetting, OD, FAAO
1.00 program credit
- Douglas K. Devries, OD
- Cecelia Koetting, OD, FAAO
1.00 program credit
Return and Revisit: A 38-Year-Old Patient Returns for Follow-up After Lotilaner Treatment
Return and Revisit: A 38-Year-Old Patient Returns for Follow-up After Lotilaner Treatment
MinuteCE®
Return and Revisit: A 38-Year-Old Patient Returns for Follow-up After Lotilaner Treatment
Douglas K. Devries, OD; Cecelia Koetting, OD, FAAO
1.00 program credit
- Douglas K. Devries, OD
- Cecelia Koetting, OD, FAAO
1.00 program credit